Loading...
DOCUMENTS
21
NOTICES
32
MOTS CLES
Patients experience
Safety
Colonic epithelial primary cells
Colorectal cancer
Microbiota
Intestinal crypts
Kidney diseases
Screening
Inhibitor
Epigenetics
Upper gastrointestinal tract
Bacteria
Primary sclerosing cholangitis
Anti-TNF agents
Neoadjuvant chemotherapy
Anti-TNF
Clinical trial
Disability
Biologics
Disease Progression
Consensus
Helicobacter pylori
PCR
IL12
Parvimonas micra
Clinical guidelines
Ustekinumab
Colon
Tuberculosis
MARKER
Cell adhesion
Cancer
Therapeutics
Fecal microbiota
HIV
Colon cancer
Drug
MORTALITY
Microbiote
Crohn's disease
Effectiveness
Rituximab
Survival
IBD
Patient-reported outcome
Dysbiosis
Cost effectiveness
IL23
Colorectal cancer Colibactin and lipids
Ulcerative colitis
Maintenance therapy
Colectomy
CARCINOGENESIS
Immune cells
Epigénétiques
Thérapie ciblée
Original Article Clinical
Gene methylation
Vedolizumab
DNA methylation
Méthylation
Contraindication
Biomarker
Genes
Inflammatory bowel diseases
COLON-CANCER
Venous thromboembolism
Stricture
Methylation
Monitoring
Endoscopic treatment
Rituximab plus chlorambucil
Disease progression
Surgery
RISK
Alkylating agents
MICROBIOTA
Inflammatory Bowel Diseases
Inclusion
Small molecules
Acceptability
Dysbiose
Bactéries
Heart disease risk factors
Eligibility
Résistance
Resistance
Algorithm
Gene expression
Crohn’s disease
Gènes
T1118 translocation
DNA METHYLATION
MALT
Immunosuppressant
Eradication
Inflammatory bowel disease
Over 80s
Tailored therapy
18 FDG-PET/CT
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|